Asarfi Hospital has scheduled its fourth board meeting for Tuesday, August 25, 2026, at its registered office in Dhanbad, Jharkhand. The primary focus of the meeting is a strategic proposal to migrate from the BSE SME Platform to the BSE Main Board and list on the National Stock Exchange (NSE).

The board will deliberate on the eligibility requirements, regulatory due diligence, and necessary approvals for this transition. Management and professional advisors will be authorized to initiate the process and place the matter before shareholders where required. This move signals the company's intent to broaden its investor base and enhance liquidity by moving to premier exchanges.

Key Agenda Items

In addition to the listing proposal, the board has several routine corporate governance matters on its agenda:

• Directors' Report: Approval of the draft Directors' Report for the financial year ended March 31, 2026.
• Director Re-appointment: Consideration of the re-appointment of Mr. Gopal Singh, who retires by rotation at the ensuing Annual General Meeting (AGM).
• AGM Logistics: Fixing the date, time, and venue for the 21st AGM, proposed for Friday, September 18, 2026, at noon. The book closure period is proposed from September 5 to September 18, 2026.
• Auditor Appointment: Appointment of M/s Ashutosh Kumar Sinha & Co., Cost Accountants, as the Cost Auditor for FY27.

What the Numbers Show

While the filing does not disclose specific financial metrics for FY26, the decision to pursue a main board listing typically implies that the company meets the stricter net worth and profitability criteria mandated by stock exchanges for such migrations. The inclusion of this item alongside the approval of the annual report suggests the company's financial position for the just-concluded fiscal year supports this strategic step.

The meeting will also involve standard procedural items, including ascertaining quorum, noting minutes of the previous meeting, and appointing a scrutinizer for e-voting if applicable.

Asarfi Hospital Limited reported a 33.8% year-on-year increase in standalone net profit to ₹426.84 lakh for the quarter ended June 30, 2026 (Q1FY27), driven by a 32.7% surge in revenue from operations to ₹4,734.47 lakh. The growth reflects stronger operational performance across its super-specialty and oncology units, with EBITDA rising 34% YoY to ₹942 lakh and margins expanding to 20%. Consolidated net profit rose 36.7% YoY to ₹426.72 lakh on revenue of ₹4,753.41 lakh, signaling sustained demand for healthcare services and effective cost management.

The Board of Directors approved the unaudited standalone and consolidated financial results at a meeting held on August 7, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Statutory Auditors R. K. Thakkar & Co. issued limited review reports on both sets of results, confirming compliance with Accounting Standard 25 (Interim Financial Reporting) and Section 133 of the Companies Act, 2013. The company remains exempt from adopting Ind AS under the MCA notification dated February 16, 2015, applicable to SME exchange-listed entities.

Financial Performance Highlights

Standalone other income declined to ₹59.26 lakh from ₹141.63 lakh in the prior year quarter, while total expenses rose to ₹4,222.99 lakh from ₹3,280.90 lakh. Employee benefit expenses increased to ₹786.22 lakh, and finance costs stood at ₹116.92 lakh. Consolidated employee benefit expenses were higher at ₹795.85 lakh due to subsidiary operations, though overall cost structures remained aligned with revenue growth.

Operational Drivers and Segment Performance

The revenue growth was underpinned by a 31% YoY increase in inpatient department (IPD) revenue and a 44% YoY rise in outpatient department (OPD) revenue. Average Revenue Per Occupied Bed (ARPOB) improved to ₹23,498 in the Super-Specialty unit and ₹31,892 in the Cancer Unit, reflecting better realizations and an enhanced case mix. High-acuity specialties including Cardiology, Neurosciences, Orthopaedics, and Obstetrics & Gynaecology drove growth in the Super-Specialty unit, while Radiation Oncology and Medical Oncology showed improved traction at the Cancer unit.

Balance Sheet and Cash Flow Position

Total standalone assets grew to ₹20,118.11 lakh from ₹19,389.27 lakh at March 31, 2026, with property, plant, and equipment holding steady at ₹10,545.33 lakh. Capital work-in-progress more than doubled to ₹396.70 lakh, indicating ongoing infrastructure expansion. Trade receivables increased significantly to ₹6,464.56 lakh from ₹5,406.67 lakh, reflecting higher patient billing volumes. Cash and cash equivalents declined to ₹804.39 lakh from ₹1,293.71 lakh, partly due to investment outflows.

Operating activities generated ₹344.22 lakh in net cash flow for the quarter, down from ₹1,909.38 lakh in FY26 annual figures but positive for the period. Investing activities consumed ₹23.56 lakh, primarily for property and equipment purchases of ₹331.08 lakh. Financing activities used ₹393.03 lakh, driven by short-term borrowing repayments of ₹291.07 lakh and interest payments of ₹116.92 lakh, offset by long-term borrowing proceeds of ₹208.00 lakh.

What the Numbers Show

The divergence between strong revenue growth and declining other income highlights that profitability gains are operationally driven rather than reliant on non-recurring items. While trade receivables expanded by over ₹1,000 lakh quarter-on-quarter, suggesting potential collection timing pressures, the company maintained positive operating cash flows. The substantial increase in capital work-in-progress points to strategic capacity building, which may support future revenue scaling if utilization rates improve alongside current demand trends. The improvement in Return on Capital Employed (ROCE) from 14% in FY25 to 17% in FY26 further underscores efficient capital utilization.